ACTG 382--SAFETY/TOLERABILITY/ANTIVIRAL ACTIVITY OF DMP266 + NELFINAVIR

ACTG 382--DMP266奈非那韦的安全性/耐受性/抗病毒活性

• 批准号: 6309623
• 负责人: RUSSELL B. VAN DYKE
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6309623
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; child (0-11); clinical research; clinical trial phase I; combination chemotherapy; dosage; drug screening /evaluation; human subject; human therapy evaluation; pediatric AIDS; pediatric pharmacology; protease inhibitor

This is an early study to find out whether a new investigational drug called DMP 266 is safe and effective for the treatment of HIV infection. This study will also seek to identify the correct dose level in children. DMP 266 will be taken in combination with Nelfinavir. Another purpose is to find the correct dose for nelfinavir in children when it is given with DMP 266.

这是一项早期研究，旨在确定一种名为P266的新研究药物是否安全有效地治疗艾滋病毒感染。本研究还将寻求确定儿童的正确剂量水平。266将与奈非那韦联合服用。另一个目的是找到奈非那韦在儿童中与NEL266一起给药时的正确剂量。